FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1756490717> ?p ?o ?g. }

• W1756490717 endingPage "883" @default.
• W1756490717 startingPage "874" @default.
• W1756490717 abstract "Objective To evaluate 18 F ‐fluorocholine positron‐emission tomography ( PET )/computed tomography ( CT ) in restaging patients with a history of prostate adenocarcinoma who have biochemical relapse after early radical treatment, and to correlate the technique's disease detection rate with a set of variables and clinical and pathological parameters. Patients and Methods This was a retrospective multicentre study that included 374 patients referred for choline‐ PET / CT who had biochemical relapse. In all, 233 patients who met the following inclusion criteria were analysed: diagnosis of prostate cancer; early radical treatment; biochemical relapse; main clinical and pathological variables; and clinical, pathological and imaging data needed to validate the results. Criteria used to validate the PET / CT : findings from other imaging techniques, clinical follow‐up, treatment response and histological analysis. Different statistical tests were used depending on the distribution of the data to correlate the results of the choline‐ PET / CT with qualitative [ T stage, N stage, early radical prostatectomy ( RP ) vs other treatments, hormone therapy concomitant to choline‐ PET / CT ] and quantitative [age, G leason score, prostate‐specific antigen ( PSA ) levels at diagnosis, PSA nadir, PSA level on the day of the choline‐ PET / CT ( T rigger PSA ) and PSA doubling time ( PSADT )] variables. We analysed whether there were independent predictive factors associated with positive PET / CT results. Results Choline‐ PET / CT was positive in 111 of 233 patients (detection rate 47.6%) and negative in 122 (52.4%). Disease locations: prostate or prostate bed in 26 patients (23.4%); regional and/or distant lymph nodes in 52 (46.8%); and metastatic bone disease in 33 (29.7%). Positive findings were validated by: results from other imaging techniques in 35 patients (15.0%); at least 6 months of clinical follow‐up in 136 (58.4%); treatment response in 24 (10.3%); histological analysis of lesions in 17 (7.3%); and follow‐up plus imaging results in 21 (9.0%). The statistical analysis of qualitative variables, corresponding to patients' clinical characteristics, and the positive/negative final PET / CT results revealed that only whether or not early treatment with RP was done was statistically significant ( P < 0.001), with the number of positive results higher in patients who did not undergo a RP . Among the quantitative variables, G leason score, T rigger PSA and PSADT clearly differentiated the two patient groups (positive and negative choline‐ PET / CT : P = 0.010, P = 0.001 and P = 0.025, respectively). A G leason score of <5 or ≥8 clearly differentiated positive from negative PET . Trigger PSA : mean of 8 ng/mL for positive PET / CT vs 2.8 ng/mL for negative PET / CT ; PSADT : mean of 8 months for positive vs 12.6 months for negative. The optimal threshold values were: 3 ng/mL for Trigger PSA level and 6 months for PSADT ( Y ouden index/receiver operating characteristic curve). Analysing these two variables together showed that PSADT was more conclusive in patients with lower T rigger PSA levels. Analysing variables by location showed that only PSADT was able to differentiate between those with disease confined to the prostate compared with the other two locations (lymph nodes and bone), with shorter PSADT in these two, which was statistically significant ( P < 0.002). In the patient group with a PSA level of <1.5 ng/mL, 30.8% had the disease, 7% of whom had metastatic bone disease. In the multivariate logistic regression, the risks factors that were clearly independent for those with positive PET / CT were: PSA level of >3 ng/mL, no early RP , and G leason score of ≥8. Conclusion Our results support the usefulness of 18 F ‐fluorocholine PET / CT in biochemical relapse of prostate cancer after radical treatment, with an overall disease detection rate close to 50%, and it can be recommended as first‐line treatment. As mentioned above, besides T rigger PSA levels, there are other clinical and pathological variables that need to be considered so as to screen patients properly and thus minimise the number of nodular lesions and increase the diagnostic accuracy of the examination." @default.
• W1756490717 created "2016-06-24" @default.
• W1756490717 creator A5000979363 @default.
• W1756490717 creator A5002180505 @default.
• W1756490717 creator A5035211367 @default.
• W1756490717 creator A5050659775 @default.
• W1756490717 creator A5061324501 @default.
• W1756490717 creator A5066282554 @default.
• W1756490717 creator A5083597718 @default.
• W1756490717 creator A5091562107 @default.
• W1756490717 date "2015-01-21" @default.
• W1756490717 modified "2023-10-16" @default.
• W1756490717 title "Clinical utility of¹⁸F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study" @default.
• W1756490717 cites W1519965506 @default.
• W1756490717 cites W1965053728 @default.
• W1756490717 cites W1967551217 @default.
• W1756490717 cites W1971005131 @default.
• W1756490717 cites W1972606661 @default.
• W1756490717 cites W1982447130 @default.
• W1756490717 cites W1985132878 @default.
• W1756490717 cites W1985799860 @default.
• W1756490717 cites W1990235169 @default.
• W1756490717 cites W1997677667 @default.
• W1756490717 cites W2030040160 @default.
• W1756490717 cites W2035877913 @default.
• W1756490717 cites W2039499300 @default.
• W1756490717 cites W2040370548 @default.
• W1756490717 cites W2042152896 @default.
• W1756490717 cites W2043839162 @default.
• W1756490717 cites W2043943861 @default.
• W1756490717 cites W2044196464 @default.
• W1756490717 cites W2054244152 @default.
• W1756490717 cites W2064969287 @default.
• W1756490717 cites W2085776136 @default.
• W1756490717 cites W2091971817 @default.
• W1756490717 cites W2111439184 @default.
• W1756490717 cites W2136437722 @default.
• W1756490717 cites W2159398272 @default.
• W1756490717 cites W2159511117 @default.
• W1756490717 cites W2160771508 @default.
• W1756490717 cites W2470836458 @default.
• W1756490717 cites W4300900655 @default.
• W1756490717 doi "https://doi.org/10.1111/bju.12953" @default.
• W1756490717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25307619" @default.
• W1756490717 hasPublicationYear "2015" @default.
• W1756490717 type Work @default.
• W1756490717 sameAs 1756490717 @default.
• W1756490717 citedByCount "40" @default.
• W1756490717 countsByYear W17564907172015 @default.
• W1756490717 countsByYear W17564907172016 @default.
• W1756490717 countsByYear W17564907172017 @default.
• W1756490717 countsByYear W17564907172018 @default.
• W1756490717 countsByYear W17564907172019 @default.
• W1756490717 countsByYear W17564907172020 @default.
• W1756490717 countsByYear W17564907172021 @default.
• W1756490717 countsByYear W17564907172022 @default.
• W1756490717 countsByYear W17564907172023 @default.
• W1756490717 crossrefType "journal-article" @default.
• W1756490717 hasAuthorship W1756490717A5000979363 @default.
• W1756490717 hasAuthorship W1756490717A5002180505 @default.
• W1756490717 hasAuthorship W1756490717A5035211367 @default.
• W1756490717 hasAuthorship W1756490717A5050659775 @default.
• W1756490717 hasAuthorship W1756490717A5061324501 @default.
• W1756490717 hasAuthorship W1756490717A5066282554 @default.
• W1756490717 hasAuthorship W1756490717A5083597718 @default.
• W1756490717 hasAuthorship W1756490717A5091562107 @default.
• W1756490717 hasConcept C121608353 @default.
• W1756490717 hasConcept C126322002 @default.
• W1756490717 hasConcept C126838900 @default.
• W1756490717 hasConcept C127077266 @default.
• W1756490717 hasConcept C146357865 @default.
• W1756490717 hasConcept C151730666 @default.
• W1756490717 hasConcept C207886595 @default.
• W1756490717 hasConcept C2775842073 @default.
• W1756490717 hasConcept C2776235491 @default.
• W1756490717 hasConcept C2777008409 @default.
• W1756490717 hasConcept C2779466945 @default.
• W1756490717 hasConcept C2780192828 @default.
• W1756490717 hasConcept C2781406297 @default.
• W1756490717 hasConcept C2989005 @default.
• W1756490717 hasConcept C71924100 @default.
• W1756490717 hasConcept C86803240 @default.
• W1756490717 hasConceptScore W1756490717C121608353 @default.
• W1756490717 hasConceptScore W1756490717C126322002 @default.
• W1756490717 hasConceptScore W1756490717C126838900 @default.
• W1756490717 hasConceptScore W1756490717C127077266 @default.
• W1756490717 hasConceptScore W1756490717C146357865 @default.
• W1756490717 hasConceptScore W1756490717C151730666 @default.
• W1756490717 hasConceptScore W1756490717C207886595 @default.
• W1756490717 hasConceptScore W1756490717C2775842073 @default.
• W1756490717 hasConceptScore W1756490717C2776235491 @default.
• W1756490717 hasConceptScore W1756490717C2777008409 @default.
• W1756490717 hasConceptScore W1756490717C2779466945 @default.
• W1756490717 hasConceptScore W1756490717C2780192828 @default.
• W1756490717 hasConceptScore W1756490717C2781406297 @default.
• W1756490717 hasConceptScore W1756490717C2989005 @default.
• W1756490717 hasConceptScore W1756490717C71924100 @default.
• W1756490717 hasConceptScore W1756490717C86803240 @default.

• next